Origano DR180 mg

Prophylaxis of organ rejection in kidney transplant: Origano DR 180 mg is indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. It is indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant.

Immunosuppressant

Origano DR 180 mg delayed-release tablets are enteric coated formulation of mycophenolate sodium that delivers the active moiety Origano DR 180 mg. It is an immunosuppressive agent. It is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Therefore, it inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. Origano DR 180 mg has cytostatic effects on lymphocytes. It has been shown to prevent the occurrence of acute rejection of kidney and heart allotransplantation. It also decreases antibody production.

Dosage in adult kidney transplant patients: The recommended dose of Origano DR 180 mg is 720 mg administered twice daily (1440 mg total daily dose).Dosage in pediatric kidney transplant patients: The recommended dose of Origano DR 180 mg in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily). Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Origano DR 180 mg 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Origano DR 180 mg 180 mg tablets, or two Origano DR 180 mg 360 mg tablets twice daily (1440 mg daily dose).Origano DR 180 mg tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating.

Dosage in adult kidney transplant patients: The recommended dose of Origano DR 180 mg is 720 mg administered twice daily (1440 mg total daily dose).Dosage in pediatric kidney transplant patients: The recommended dose of Origano DR 180 mg in conversion (at least 6 months post-transplant) pediatric patients age 5 years and older is 400 mg/m2 body surface area (BSA) administered twice daily (up to a maximum dose of 720 mg administered twice daily). Pediatric patients with a BSA of 1.19 to 1.58 m2 may be dosed either with three Origano DR 180 mg 180 mg tablets, or one 180 mg tablet plus one 360 mg tablet twice daily (1080 mg daily dose). Patients with a BSA of >1.58 m2 may be dosed either with four Origano DR 180 mg 180 mg tablets, or two Origano DR 180 mg 360 mg tablets twice daily (1440 mg daily dose).Origano DR 180 mg tablets should be taken on an empty stomach, 1 hour before or 2 hours after food intake. Tablets should not be crushed, chewed, or cut prior to ingesting. The tablets should be swallowed whole in order to maintain the integrity of the enteric coating.

Caution should be exercised with concomitant administration of Antacids, Azathioprine, Cyclosporin, Rifampin, Sevelamer, Cholestyramine, Acyclovir, Metronidazole, Hormonal contraceptives as these medicines may decrease Origano DR 180 mg concentration.

Origano DR 180 mg delayed-release tablets and Mycophenolate mofetil tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent.

The most common adverse reactions (≥20%) associated with the administration of Origano DR 180 mg are anemia, leukopenia, constipation, diarrhea, vomiting, dyspepsia, urinary tract infection, CMV infection, insomnia, and postoperative pain.

Pregnancy Category D. Can cause fetal harm.Lactation: Discontinue Origano DR 180 mg or discontinue nursing while on treatment or within 6 weeks after stopping therapy. Take into consideration the importance of the drug to the mother.

Origano DR 180 mg tablets are used with caution because it- Can cause embryofetal toxicity Can increase new or reactive viral infections Can cause blood dyscrasias including pure red cell aplasia Can cause serious GI tract complications (gastrointestinal bleeding, perforations and ulcers) May increase the risk of developing lymphomas and other malignancies, particularly of the skin Use of live vaccine should be avoided during treatment with Origano DR 180 mg

No data are available with regard to overdose.

Store at 25° C and Keep out of reach of children.

Immunosuppressant

Origano DR 180 mg delayed-release tablets are enteric coated formulation of mycophenolate sodium that delivers the active moiety Origano DR 180 mg. It is an immunosuppressive agent. It is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). Therefore, it inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. Origano DR 180 mg has cytostatic effects on lymphocytes. It has been shown to prevent the occurrence of acute rejection of kidney and heart allotransplantation. It also decreases antibody production.

Pregnancy Category D. Can cause fetal harm.Lactation: Discontinue Origano DR 180 mg or discontinue nursing while on treatment or within 6 weeks after stopping therapy. Take into consideration the importance of the drug to the mother.